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Abstract 
In this paper, we develop a theoretical contribution towards the understanding of the 
complex behavior of conjoint tumor-normal cell growth under the influence of           
immuno-chemotheraputic agents under simple immune system response. In particular, 
we consider a core model for the interaction of tumor cells with the surrounding normal 
cells. We then add the effects of a simple immune system, and both immune-suppression 
factors and immuno-chemotherapeutic agents as well. Through a series of numerical 
simulations, we illustrate that the interdependency of tumor-normal cells, together with 
choice of drug and the nature of the immunodeficiency, leads to a variety of interesting 
patterns in the evolution of both the tumor and the normal cell populations. 
Key words: Aging, tumor cell dynamics, normal cell dynamics, tumor-normal cell interactions, 
chemotherapy, Immune system, Immunotherapy, Immunodeficiency 
Introduction 
Every day, clinical and experimental studies 
provide evidence of new features that can influence 
cancer dynamics and its treatment methodologies 
[1-4]. Ongoing research efforts aim to provide a 
clearer picture of the evolution of the tumor and 
normal cells with the objective of improving cancer 
treatment protocols. 
During cancer progression, tumor cells interact 
with the surrounding environmental components 
such as normal cells, immune cells or therapeutic 
agents that have been externally added to the system. 
The nature of the tumor-environment interaction is 
complex and depends upon many factors such as host 
age, sex, and many more. They are all key factors that 
can lead to complex patterns of tumor cell evolution. 
Considering the tumor-environment interaction, 
it has already been demonstrated that the growth of 
normal and tumor cells are co-dependent due to their 
biochemical and biomechanical interactions [5-12]. 
Additionally, researchers have experimentally ex-
plored the interaction of tumor cells with the host 
immune system and the suppressive effects of the 
immune cells in tumor progression [13-18]. Experi-
mental evidence demonstrates that there is an altera-
tion of the level of immune components during the 
various stages of cancer growth. This underlines the 
key role of the immune system in cancer dynamics [1, 
19]. Understanding the intrinsic growth of tumor 
cells, together with the interaction with their sur-
roundings, has led to several single and mul-
ti-therapeutic strategies to modulate and control the 
growth of these cells.  
We can, however, examine the evolution of tu-
mor and normal cells and complexity of the system 
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through the use of computational and mathematical 
modeling and simulation. For example, the interac-
tion of tumor cells with surrounding normal cells was 
first mathematically introduced by Witten [20-23]. The 
interaction of immune system and different thera-
peutic agents with tumor cells has been theoretically 
modeled and studied by several research groups 
[24-30].  
In this paper, we make use of Witten’s [23] core 
tumor-normal cell model. However, we modify it as 
follows. First, we model the interaction of the immune 
system with the conjointly growing tumor-normal 
cells. Then, we assume a deficiency in the immune 
system due to the presence of immune-suppressing 
factors such as viruses. Additionally, we add a dif-
ferent therapeutic approach to this modified model. 
We then investigate the evolution of normal and tu-
mor cells through a series of computational simula-
tions. Finally, we offer subsequent biological inter-
pretations of the simulation results. 
Building the Mathematical Model 
Introducing the Conjoint Core Model 
In the core model, both the normal and tumor 
cells independently increase according to a logistic 
growth law (other types of independent growth 
model may be used). The interaction of tumor with 
normal and normal with tumor cells is described by 
the second term in the model where the normal cells 
are denoted by N and the tumor cells are denoted by 
T. Thus, the original core model [20-23] expresses one 
possible dynamics for the interplay of normal and 
tumor cells and it is given by the following system of 
equations: 
 
where T, N, KT, KN, rT, rN are the total number of tumor 
cells, the total number of normal cells, the carrying 
capacity of the tumor cells, the carrying capacity for 
the normal cells, and the per capita growth rate for the 
tumor and normal cells respectively and κ is the tu-
mor-normal cell coupling constant. The second terms 
in each equation represent the nor-
mal-tumor/tumor-normal cell interactions. Here, β 
has the units of 1/time (where time is measured in 
arbitrary units depending upon the timescale of in-
terest in the problem) and ρ0 is measured in units of 
cells. T* is the critical number of tumor cells and as T 
exceeds the critical size T*, the tumor cells increase 
their ability to inhibit normal cell growth. This be-
havior is illustrated in Figure 1. Figure 1A, shows the 
independent growth of the normal and tumor cells 
(no interactions). However, in the conjoint growth 
illustrated in Figure 1 B, we can see the dependency 
between the cell populations. As the size of the tumor 
cell population, T, exceed the critical size, T*, the size 
of the normal cell population, N, begins to decrease.  
 
 
Figure 1: Green curve: Evolution of normal cell population. Red curve: Evolution of tumor cells. Simulation pa-
rameters: r N=0.4, r T =0.3, K T=1.2. 10
6
, K N=10
6
. A: There is no interaction between normal cells and tumor cells (both 
populations undergo logistic growth), κ=0, β=0. B: Normal and tumor cells are allowed to interact with each other, κ 
=0.028, β =1, ρ0=1, ρ1=1000, T*=3.10
5
, N0=1, T0=1. As the size of the tumor cells T exceed the critical size, T* (dashed 
line), the size of normal cells N starts decreasing. 
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Immune-Tumor interaction 
Panetta & Kirschner mathematically modeled 
the interaction of tumor cells with the immune system 
and immune-therapeutic agents [31, 32]. This model, 
which has been used in other studies [33, 34], ex-
plained clearly the equilibrium of the tumor-immune 
system as well as the oscillatory behavior of the tumor 
size around the equilibrium. In this paper, we add the 
concepts of the interaction of the immune system es-
tablished by Panetta and Kirschner to our conjoint 
growth model. As explained in Kirschner’s model, 
two variables are considered to be the main immune 
system components: the first is activated im-
mune-system cells (effector cells) including T cells and 
other immune cells that are cytotoxic to tumor cells. 
E(t) represents the effector cells in the modified model 
equations below. The second immune system com-
ponent is the concentration of IL-2, which is the main 
cytokine responsible for T cells activation, growth and 
differentiation at the tumor site. This variable is ex-
pressed by I(t). 
The loss of tumor cells, due to the im-
mune-effector cells can be characterized with a 
Michaelis-Menten interaction term, aET/(g2 + T). Here, 
‘a’ is the rate of clearance of tumor cells as a result of 
these two populations and g2 is the half-saturation for 
cancer clearance. Also, the activation happens because 
of the presence of IL-2 hormones and is given by the 
term p1EI/(g1+ I). This is also a Michaelis-Menten term. 
Here p1 is the proliferation rate of immune cells and g1 
is the half-saturation for the proliferation term. To 
express the natural death of effector cells, the term 
-µ3E is added. In this term µ2 is the death rate of the 
immune cells. The change in concentration of IL-2 is 
expressed as: p2TE/(g3 + T), which is the activation due 
to the presence of the tumor. In this term, p2 is the 
production rate of the effector molecules and g3 is the 
half-saturation of production. Finally, -µ2I, is the nat-
ural loss of IL-2 by the rate of µ2. 
Adding Chemo/Immuno-Therapy to the Im-
mune-Tumor Interaction 
Many factors can be considered to be immune 
suppression factors, including immune-suppression 
viruses. These viruses can infect the activated immune 
cells. As a result of this infection, the population of 
activated cells decreases and this leads to a weakened 
immune system. In such a case, the treatment can 
consist of immune boosting drugs such as Interleu-
kin-2 (IL-2) [35]. Kirschner [36, 37] mathematically 
characterized the general interaction of the Human 
Immunodeficiency Virus and activated immune cells. 
The presence of immune suppression factors reduces 
the efficiency of the immune system in battling tumor 
cells. These same mathematical terms are, thus, added 
to our model to explain a simple possible immune 
deficiency [35]. Similar to the approach of Kirshner, 
the production source of virus, V(t), can be introduced 
as ηV/(b+V) where η is the production rate and b is the 
saturated term. -µ1V expresses the natural death of 
viruses at rate of µ1. The interaction between effector 
cells and viruses can reduce the size of both popula-
tions with different rates. This is expressed as: - αVE 
and -γVE to illustrate the interaction between virus 
and effector cells. As a result of this interaction, the 
immune effector cells decrease the population of vi-
ruses at rate α. Additionally, viruses infect some of the 
effector cells and, therefore, the population of unin-
fected effector cells decreases at the rate γ. 
Treatment Characterizations  
To control cancer progression, many approaches 
can be implemented, among them chemotherapy, 
immunotherapy or some combination of the two. The 
enhancement of the immune system by immu-
no-therapeutic agents that directly boost the number 
of T cells has a key role in the reduction of both the 
number of tumor cells and viruses. Chemotherapeutic 
agents can kill the tumor population in a 
dose-dependent manner [38, 29]. Feizabadi and Wit-
ten [28] have investigated the effect of the chemo-
therapeutic agents on a conjoint system of tumor and 
normal cells. However, chemotherapeutic agents are 
cytotoxic not only to tumor cells, but also to normal 
and activated cells as well. Clinical evidence also in-
dicates that some of the anticancer agents can control 
the replication of viruses in a dose-dependent man-
ner. Some data supports and some discourage the use 
of anticancer agents for immuno-deficient virus 
treatment. On the one hand, some drugs have strong 
anti-activity virus effects, but not the ability to kill 
rapidly proliferating tumor cells. On the other hand, 
some of the anti-proliferating drugs may not have a 
positive effect on controlling viruses [39]. Conse-
quently, it is obvious that therapeutic potential de-
pends upon the impact and the cross-toxicity of the 
drug on different components of the system. 
Knowledge of these pharmacokinetic interactions can 
improve the future architecture of both drugs and 
treatment strategies.  
Gardner [40], first suggested the general term 
aφ(1-e- ξ
MC)φ for φ = T, N, E as a means of describing as 
drug interaction term. In our model, we have consid-
ered cellular interaction with chemotherapeutic 
agents and we have allowed them to have some de-
gree of toxicity to T, N, and E cells. Additionally, the 
immunotherapeutic agent is described by the term 
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aEE(1-e ξ
MI) and it acts as an immune-boosting agent. In 
the interaction terms, the constants MC and MI rep-
resent the chemotherapy and immunotherapy drug 
concentrations and ξ is linked to the drug pharmaco-
kinetics and is assumed to have the value ξ = 1 in this 
preliminary study [28, 29]. 
ODE Model: Mathematical Construction of the 
Modified Model 
Combining all of the aforementioned interaction 
terms, the evolution of the full system can be ex-
pressed as follows: 
 
 
 
The evolution of the above full system is dis-
cussed in the following sections. 
Model Simulation 
Simulation of the compartmental evolution was 
carried out using Mathematica V7.0. Our choice of 
parameters is based on values previously introduced 
or obtained from references in the literature. The cita-
tion for each parameter along with the associated pa-
rameter values is given in Table 1. However, given the 
generality of the model, alternate parameter values 
may also be implemented allowing the user to further 
investigate the kinetics of the various system compo-
nents.  
Table 1: Simulation Parameters 
Parameter Units Description Estimated Value Reference Source 
rT Time-1 Growth rate for the tumor cells 0.3 [28] 
KT Cells Carrying capacity of tumor cells 1.2*106 [28] 
β Time-1 Normal-tumor cell interaction rate 01 [28] 
ρ0 Cells Interaction clearance term 1 [28] 
ρ1 Cells Half-saturation for interaction 1000 [28] 
a Time-1 Cancer clearance term 1 [31] 
g2 Cells Half-saturation for cancer clearance 105 [31] 
rN Time-1 Growth rate for the normal cells 0.4 [28] 
KN Cells Carrying capacity of normal cells 106 [28] 
κ Time-1 Tumor-normal cell interaction rate 0-0.028 [28] 
T* Cells Critical size of tumor 3*105 [28] 
c Time-1 Antigenicity 0.005 [31] 
µ2 Time-1 Death rate of immune cells 0.03 [31] 
p1 Time-1 Proliferation rate of immune cells 0.1245 [31] 
g1 Cells Half-saturation proliferation term 2*107 [31] 
p2 Time-1 Production rate of effector molecules 5 [31] 
g3 Cells Half-saturation of production 30 [31] 
µ3 Time-1 Half-life of effector molecules 10 [31] 
µ1 Time-1 Death rate of viruses 0.03 - 
b Viruses Half-saturation of virus population 5 - 
α Time-1 Effector cell-virus interaction rate 2.5*10-4 - 
η Time-1 Production rate of viruses 3*104 - 
γ Time-1 Virus-effector cell interaction rate 0.005 - 
 Concentration-1 Pharmacokinetic parameter 1 [29] 
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Figure 2: A: Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2 
Concentration. The common parameters are the same amount as Figure 1. The new parameters are: a=1, g2=10
5
, 
c=0.005, µ2=0.03, p1=0.1245, g1=2*10
7
, p2=5, g3=30, µ3=10. In this figure, Red curve represents the interaction with 
the immune system. The Black curve represents the interaction of the system with just chemotherapeutic agents 
when aT[1-exp
(-MC)
]=0.05, and aN[1-exp
(-MC)
)=aE[1-exp
(-MC)
]=0.01. The Orange curve represents the interaction with the 
chemotherapeutic agent when the killing effect of the chemotherapeutic agents on effector and normal cells is 
minimum. In this case, aT[1-exp
(-MC)
]=0.05 and aN[1-exp
(-MC)
]=aE[1-exp
(-MC)
]=0.001. The Blue curve represents the 
interaction of the system with the chemotherapeutic agents with the same parameters as the orange graph and the 
immune boosting agents where aEE[1-exp
(-MI)
]=0.002. The Green curve represents the same case as the blue case with 
higher dosage of the immune boosting drugs, aEE[1-exp
(-MI)
]=0.004. As explained in the text, the most effective 
therapy is the case associated to the implementation of the chemotherapeutic agents that majorly kill tumor cells 
together with effector cells boosting drugs. Some oscillatory behavior can be seen though around the equilibrium 
when both agents are implemented before reaching the final equilibrium. 
 
 
The behavior of tumor, normal, effector cells and 
IL-2 concentration in a conjoint model is studied using 
different simulation assumptions. In Figure 2, the 
behavior of the components of the system is illus-
trated for the case where the system of tumor-normal 
cells interacts with the host immune system compo-
nents.  
As the system of tumor and normal cells inter-
acts with the immune cells, the amount of effector 
cells and the concentration of IL-2 are increased due to 
the presence of the tumor cells, Figure 2C and 2D. As 
a result of the cancer clearance effect of the effector 
cells, the population of the tumor cells decreases and 
the population of the normal cells increases as com-
pared with the dynamics illustrated in Figures 2A, 2B. 
Chemotherapeutic agents are introduced into the 
system of tumor-normal cells that are already inter-
acting with the immune system and the evolution of 
the system components changes. We first consider the 
case in which the chemotherapeutic agent kills tumor 
cells. These agents are also assumed to kill normal and 
immune cells due to their toxicity. However, it is as-
sumed that the killing rate of the chemotherapeutic 
agent is higher for the tumor cells than for the normal 
and the effector cells. Therefore, we observe a slight 
decrease in the size of the tumor cell population. As 
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the size of the tumor cell population decreases, the 
population of the effector cells and the IL-2 levels de-
crease as well. The Figure 2 black curves illustrate the 
chemotherapeutic interaction.  
Ideal chemotherapeutic agents (Orange curves in 
Figure 2) are agents that are capable of killing signif-
icant numbers of tumor cells with very minimal ef-
fects on the normal and the effector cell populations. 
In this case, the shrinkage of tumor cells is significant. 
The population of the tumor cells decreases and both 
the tumor cells and normal cells experience oscilla-
tions around their equilibrium during the chemo-
therapeutic interaction. If we then add additional 
immunotherapeutic agents, the final population of 
tumor cells decreases significantly. However, the in-
teraction of the tumor cell population with immu-
no-chemotherapeutic agents exhibits an increased 
amplitude of the oscillation before reaching a steady 
state behavior (Blue and Green curves in Figure 2). 
This shrinkage is combined by an oscillatory 
behavior with small amplitude in oscillation. The 
system expresses a better response in terms of a re-
duction in the size of the tumor cells, when in the 
presence of chemotherapeutic agents, and the im-
munotherapy is added. In the current case, the final 
size of the tumor cell populations is significantly 
smaller. However, the more effective immunothera-
peutic agents cause oscillations with larger amplitude 
before reaching to a steady state behavior. 
In our final case, we consider the scenario in 
which the immune system has reduced effectiveness. 
In this particular case, we assume that the reduction is 
due to a viral load. Due to the existence of an im-
mune-suppressant, the population of the effector cells 
at the steady state decreases (Figure 3D) and, subse-
quently, the population of the tumor cells increases 
(Figure 3A). Also, in the immune-deficient system, the 
growth of the effector cells demonstrates a delayed 
onset as compared to the system with no deficiency. 
Additionally, we observe that the growth of effector 
cells is slower in the presence of this deficiency. In the 
absence of any immune deficiency, we simulated the 
behavior of the tumor cells under an im-
mune-chemotherapeutic agent. As discussed above, 
under the effect of the immuno-chemotherapeutic 
drugs, the population of effector cells decreases, while 
there is an oscillatory behavior before reaching the 
steady state. In the presence of an immune system 
deficiency, in order to reach a nearly equivalent 
steady state after therapy, we first used the same 
amount of chemotherapy and increased the immu-
notherapeutic agent. We observe that a much larger 
amount of this same agent is needed in order for the 
system to approach the same steady state (Figure 
3-Green). Alternatively, in order to reach the same 
steady state, in the presence of any limitation in the 
dosage of the immuno-therapeutic agent, one can 
slightly increase the amount of immuno-therapeutic 
agent together with a simultaneous increase in the 
amount chemotherapeutic agent (Figure 3, 
Dashed-Green). 
Closing Remarks 
In this work, we modified Witten’s [23] conjoint 
normal-tumor cell model in order to incorporate the 
presence of a simple immune system. The evolution of 
the system variables was investigated via computer 
simulation. Various cases were considered. We first 
considered the effect of a chemotherapeutic agent on 
the system. We investigated different therapeutic ap-
proaches to control the size of the tumor cell popula-
tion. We then considered the possibility of the exist-
ence of a virally induced deficiency in the immune 
system function. In this scenario, the deficiency di-
rectly affected the behavior of tumor and normal cells 
as well as the immune system components. Among 
the possibilities, chemotherapeutic together with 
immunotherapeutic agents demonstrated the best 
outcome in terms of reducing the size of the tumor in 
the absence of any deficiency. In the presence of im-
mune deficiency factors, even the most successful 
therapeutic agents needed to be re-evaluated to obtain 
similar outcomes in terms of the reduction in size of 
the tumor cells, as compared to a properly functioning 
immune system in the absence of any deficiency. 
Simulations demonstrated that either the level of 
immunotherapeutic agents should significantly in-
crease or the level of chemotherapeutic together with 
immunotherapeutic agents should increase. This in-
crease may control the size of the tumor cell popula-
tion, but the toxicity of chemotherapy reduces the 
immune system and the ability to battle the virus, 
which may subsequently lead to death as a result of 
infection. 
In an attempt to control the size of the tumor cell 
population, through different therapeutic protocols, it 
is necessary to first evaluate any factors, which may 
suppress the functionality of the immune system. Se-
cond, the nature of the therapeutic agents and the way 
that they interact with normal, tumor, immune cells 
and immunodeficiency factors needs to be investi-
gated prior to implementation. In short, more infor-
mation regarding the intrinsic interaction among dif-
ferent types of cells together with the interaction of 
each group of cells and externally added agents can 
lead to selecting a better treatment approach and 
reaching a better outcome in the reduction and control 
of the cancer. 
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Figure 3: In this figure the system behavior under the influence of immunodeficiency viruses is investigated. A: 
Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2 Concen-
tration. E: Evolution of Virus. Same common parameters are implemented as before. The specific parameters are 
η=3*104, b=5, γ=0.005, α=2.5*10-4, µ1 =0.03. The Red curve represents the behavior of the components in the 
presence of the virus. Black: General chemotherapy is then introduced and then improved to the chemotherapeutic 
agents with major killing effects on tumor cells. Blue: the effector boosting drugs is added. Green: the dosage of the 
immune boosting drugs is significantly increases aEE[1-exp
(-MI)
]=0.02 to almost reach to the equilibrium of the system 
in the absence of any viruses. In dashed-Green line, instead of significantly increasing the dosage of immune boosting 
drugs to reach to the equilibrium discussed in Figure 2, both chemotherapeutic and immunotherapeutic drugs was 
increased, aEE[1-exp
(-MI)
]=0.01, aT[1-exp
(-MC)
]=0.05. 
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